Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Akzo Nobel Market-Perform (DPA-AFX) +++ AKZO NOBEL Aktie -4,33%

EISAI Aktie

 >EISAI Aktienkurs 
22.86 EUR    -2.4%    (TradegateBSX)
Ask: 23.28 EUR / 215 Stück
Bid: 22.82 EUR / 220 Stück
Tagesumsatz: 254 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
EISAI Aktie über LYNX handeln
>EISAI Performance
1 Woche: +3,2%
1 Monat: +19,3%
3 Monate: -12,9%
6 Monate: -12,2%
1 Jahr: +1,3%
laufendes Jahr: -7,4%
>EISAI Aktie
Name:  EISAI CO. LTD
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3160400002 / 855526
Symbol/ Ticker:  EII (Frankfurt)
Kürzel:  FRA:EII, ETR:EII, EII:GR
Index:  Nikkei225
Webseite:  https://www.eisai.com/
Profil:  Eisai Co., Ltd. is a major pharmaceutical company specializing in the research, development, and manufacture of innovative pharmaceuticals. Its primary function is to deliver prescription drugs and therapies aimed at treating neurological disorders, ..
>Volltext..
Marktkapitalisierung:  6529.98 Mio. EUR
Unternehmenswert:  6583.79 Mio. EUR
Umsatz:  4553.46 Mio. EUR
EBITDA:  440.01 Mio. EUR
Nettogewinn:  212.72 Mio. EUR
Gewinn je Aktie:  0.75 EUR
Schulden:  1264.18 Mio. EUR
Liquide Mittel:  1353.95 Mio. EUR
Operativer Cashflow:  338.31 Mio. EUR
Bargeldquote:  0.72
Umsatzwachstum:  -7.5%
Gewinnwachstum:  -26.54%
Dividende je Aktie:  0.89 EUR
Dividendenrendite:  3.73%
Dividendenschätzung:  3.64%
Div. Historie:  30.03.26 - 0.43682963€
29.09.25 - 0.455808€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  EISAI
Letzte Datenerhebung:  13.07.26
>EISAI Kennzahlen
Aktien/ Unternehmen:
Aktien: 282.11 Mio. St.
Frei handelbar: 90%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 10543
Umsatz/Mitarb.: 0.43 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 2%
Bewertung:
KGV: 31.87
KGV lG: 22.33
KUV: 1.44
KBV: 1.37
PEG-Ratio: -
EV/EBITDA: 14.96
Rentabilität:
Bruttomarge: 76.83%
Gewinnmarge: 4.67%
Operative Marge: 4.87%
Managementeffizenz:
Gesamtkaprendite: 2.72%
Eigenkaprendite: 4.43%
>EISAI Peer Group
Gesundheit, Demenz/ Alzheimer- Behandlung, Neurologische Erkrankungen/ Schlaganfälle, Onkologie/ Krebs- Behandlung
 
13.07.26 - 10:03
 Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer′s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer′s Association International Conference® (AAIC®) 2026 (PR Newswire)
 
Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug's future clinical development TOKYO, July 13, 2026 /PRNewswire/ -- Eisai Co., Ltd. today......
13.07.26 - 06:12
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous......
13.07.26 - 06:06
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous......
12.07.26 - 17:30
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (Cision)
 
Stockholm, Sweden, July 12, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care...
30.06.26 - 08:57
 New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 (PR Newswire)
 
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its......
30.06.26 - 08:48
 New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 (PR Newswire)
 
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its......
29.06.26 - 13:32
 Eisai to Showcase Alzheimer′s Disease Portfolio with More Than 50 Presentations at the Alzheimer′s Association International Conference® 2026 (AAIC®) (PR Newswire)
 
TOKYO, June 29, 2026 /PRNewswire/ -- Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's......
15.06.26 - 22:12
 Japan′s Eisai to pump $64m into UK plant to package injectable drugs (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
01.06.26 - 13:03
 Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer′s Disease and Related Dementias (PR Newswire)
 
Expansion of Magnolia Meals at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners NUTLEY, N.J., June 1, 2026 /PRNewswire/ -- Eisai Inc. today announced the expansion of its Magnolia Meals at Home® program to support the......
25.05.26 - 12:30
 Eisai Expects Revenue Of JPY 1 Trillion For 2028 (AFX)
 
TOKYO (dpa-AFX) - Eisai Co., Limited (ESALY.PK, ESALF.PK, 4523.T, EII.SG), a Japanese pharmaceutical company, said on Monday that it expects revenue of JPY 1 trillion for fiscal 2028, helped by th......
25.05.26 - 09:39
 BioArctic′s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day (PR Newswire)
 
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion......
20.05.26 - 14:09
 Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026 (PR Newswire)
 
Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell......
20.05.26 - 09:42
 BioArctic Interim Report for the period January - March 2026 (PR Newswire)
 
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
20.05.26 - 09:36
 BioArctic Interim Report for the period January - March 2026 (PR Newswire)
 
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
20.05.26 - 07:01
 Interim Report for the period January – March 2026 (Cision)
 
Strong financial performance with commercial milestone reached Events during the first quarter 2026 · Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment · Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks · The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China · New long‑term and real‑world data for Leqembi, presented at the AD/PD™ conference in...
15.05.26 - 11:18
 Eisai: Rekordumsatz, aber Gewinnrückgang (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 10:02
 Eisai Full-year Profit Falls, But Revenue Rises; Forecasts Higher Profit, Revenue In Fiscal 2026 (AFX)
 
TOKYO (dpa-AFX) - Eisai Co Ltd (ESALY.PK) on Friday reported lower profit for fiscal 2025, while revenue increased from the previous year.Profit before tax fell 16.5% to 51.0 billion yen from 61.1......
15.05.26 - 09:01
 Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) (PR Newswire)
 
STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding......
15.05.26 - 08:57
 Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) (PR Newswire)
 
STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding......
15.05.26 - 08:36
 Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027) (Cision)
 
Stockholm, Sweden, May 15, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Absicht eines Christen, der ein Streitgespräch über die Glaubenswahrheiten führt, muß nicht darauf zielen, den Glauben zu beweisen, sondern den Glauben zu verteidigen. - Hl. Thomas von Aquin
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!